GlassScriptPhysician profile
Kaitlin N Lynch
NPI 1376066571
$2,116.01
in general payments reported to CMS, 2019-2025
32 companies · $1,337 in 2025
The $1,337 reported for 2025 was more than what 89% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $240 · 2022: $246 · 2023: $231 · 2024: $61.91 · 2025: $1,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,336 · Education: $294.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,335.93 |
| Education | $293.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $562.11 | 2025 | Trodelvy |
| Janssen Pharmaceuticals, INC | $235.51 | 2021-2023 | Invega Sustenna, Invega Trinza, Spravato |
| Novo Nordisk INC | $180.29 | 2022-2023 | Wegovy |
| Lilly USA, LLC | $164.15 | 2021-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $146.15 | 2021-2025 | |
| Daiichi Sankyo INC. | $74.47 | 2025 | Injectafer, Enhertu, Vanflyta |
| Incyte Corporation | $71.89 | 2025 | Jakafi |
| E.R. Squibb & Sons, L.L.C. | $70.88 | 2025 | Opdivo |
| Caris Mpi, INC. | $63.70 | 2025 | Mi Cancer Seek |
| Novartis Pharmaceuticals Corporation | $53.68 | 2025 | |
| Merck Sharp & Dohme LLC | $41.36 | 2025 | Lynparza, Keytruda, Keytruda Qlex |
| Genzyme Corporation | $35.45 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $34.87 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $33.38 | 2025 | Calquence |
| Exact Sciences Corporation | $30.04 | 2025 | Cologuard Collection Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $29.54 | 2025 | |
| Stemline Therapeutics INC. | $25.35 | 2025 | Orserdu |
| Amarin Pharma, INC. | $24.82 | 2021-2022 | |
| Glaxosmithkline, LLC. | $24.35 | 2021-2022 | |
| Sobi, INC | $23.75 | 2025 | |
| Azurity Pharmaceuticals, INC. | $20.92 | 2025 | Vivimusta, Danziten |
| Pharmacosmos Therapeutics INC. | $18.83 | 2025 | Monoferric |
| Pharmaessentia USA Corporation | $18.75 | 2025 | Besremi |
| Janssen Biotech, INC. | $18.75 | 2025 | Tecvayli |
| Geron Corporation | $16.68 | 2025 | Rytelo |
| Biohaven Pharmaceutical Holding Company LTD. | $16.20 | 2022 | |
| Sanofi-Aventis U.S. LLC | $15.00 | 2022 | |
| Pfizer INC. | $14.75 | 2021 | |
| Horizon Therapeutics Plc | $13.54 | 2022 | |
| Almatica Pharma LLC | $12.93 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.99 | 2021 | |
| Dexcom, INC. | $11.93 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kaitlin Lynch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.